Study finds it’s safe to treat HER2-positive breast cancer with trastuzumab and adjuvant radiation

	Tweet

Standard adjuvant treatment for HER2-positive breast cancer patients, following primary surgery for their cancer, is Trastuzumab (Herceptin)––typically used in combination with chemotherapy. However, a new study by researchers at Fox Chase Cancer Center reports that it may be safe to treat these patients with both Trastuzumab and adjuvant radiation therapy. The study will be presented today at the annual meeting of the American Society for Radiation Oncology (ASTRO).

“Our study evaluated the skin toxicity and early cardiac toxicity of concurrent Trastuzumab and radiation therapy treatment in the adjuvant setting,” says Penny Anderson, M.D., radiation oncologist at Fox Chase and lead author on the study. “We found that there was an extremely low rate of acute radiation dermatitis and cardiac toxicity in patients who received this type of treatment.”

The study followed 85 breast cancer patients who received adjuvant Trastuzumab while also receiving a course of adjuvant radiation therapy, as well as 85 breast cancer patients who only received adjuvant radiation therapy.

Acute dermatitis was grade 2 in 15% and grade 3 in 2% of the patients receiving concurrent treatment, likewise grade 2 and grade 3 dermatitis was observed in 14% and 2 % of patients only receiving radiation therapy––there was only one patient who developed a grade > 2. There were no differences in cardiac toxicity between the two groups.

“The results of this study show that it is safe to use both Trastuzumab and radiation therapy in an adjuvant setting, when clinically indicated,” adds Anderson. “We would like to see longer follow-up to evaluate the potential differences in late cardiac toxicity.”

###

Fox Chase Cancer Center is one of the leading cancer research and treatments centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet status for excellence three consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. For more information, visit Fox Chase’s web site at http://www.fccc.edu or call 1-888-FOX-CHASE or 1-888-369-2427.

---
Contact: Diana Quattrone

215-728-7784
Fox Chase Cancer Center

RELATED STORIES:
Broken genomes behind breast cancers   Obese women play cancer roulette   Fish Oil May Reduce Risk of Breast Cancer   Exercise Improves Quality of Life for People with Breast Cancer   Identification of 5 genes involved in the metastasis of breast tumors to the lung   City-dwelling women at greater risk for breast cancer   Online prayer may benefit breast cancer patients   Genetic Breast Cancer Assessment Eases Stress for Women at Risk   Recurrence of breast cancer after more than 10 years is an important indicator of survival   Alcohol may influence breast cancer recurrence   Breast Density Linked to Increased Cancer Recurrence Risk   Rate of Breast Cancer in Italy Significantly Higher than Previously Reported   Web Tool Aims to Improve the Workplace for Breast Cancer Survivors   Teaching Breast Health Early to Reduce Breast Cancer Mortality in D.C.   Extreme weight gain raises risk for recurrence among breast cancer survivors   Device for testing breath for the presence of metabolites associated with breast cancer   Chemotherapy is as effective before breast cancer surgery as after   First prospective analysis links breast and pancreatic cancer risk with lynch syndrome   For Women with Breast Cancer Gene, Psychological Factors Affect Choices about Risk-Reducing Surgery   Calcium pills no help against breast cancer: study   Prospective surveillance model emerges as standard of care for breast cancer treatment   Racial Disparities Exist in Radiation Therapy Rates for Early Stage Breast Cancer

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]